Immunovant (IMVT) Assets (2018 - 2026)

Immunovant's Assets history runs 9 years deep, the most recent figure standing at $957.0 million for Q1 2026.

• Quarterly Assets rose 23.29% year-over-year to $957.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $957.0 million (up 23.29% YoY) and the FY2026 annual result came in at $957.0 million, up 23.29% from the prior year.
• Assets was $957.0 million for Q1 2026 at Immunovant, down from $1.1 billion in the prior quarter.
• Across five years, Assets topped out at $1.1 billion in Q4 2025 and bottomed at $292.1 million in Q3 2023.
• A 5-year average of $578.9 million and a median of $515.7 million in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2024 — Assets slumped 40.83% — and 2025, when it soared 150.01%.
• Immunovant's Assets stood at $456.2 million in 2022, then surged by 55.94% to $711.4 million in 2023, then slumped by 40.83% to $420.9 million in 2024, then surged by 150.01% to $1.1 billion in 2025, then retreated by 9.06% to $957.0 million in 2026.
• Business Quant data shows IMVT's Assets at $957.0 million in Q1 2026, $1.1 billion in Q4 2025, and $583.0 million in Q3 2025.